Near-infrared (NIR) fluorescent agent for in vivo imaging and other applications.
You successfully added item(s) to your cart
For laboratory use only. This product is intended for animal research only and not for use in humans.
Please enter valid quantity
Please login to add favorites
NULL OR EMPTY CART
MMPSense 680 is a protease activatable fluorescent in vivo imaging agent that is activated by key matrix metalloproteinases (MMPs) including MMP-2, -3, -9 and -13. MMPSense 680 is optically silent in its unactivated state and becomes highly fluorescent following protease-mediated activation.
MMP activity is involved in many disease-related processes including cancer progression, invasion and metastasis, rheumatoid arthritis, pulmonary diseases and areas of cardiovascular disease. MMPSense 680 may be used to monitor the progression of these diseases or to evaluate the potential therapeutic efficacy of drugs targeting the underlying mechanisms involved in these diseases.
|Fluorescent Agent Type||Activatable|
|Optical Imaging Classification||Fluorescence Imaging|
|Product Brand Name||MMPSense|
|Quantity in a Package Amount||1.0 Units|
|Shipping Condition||Blue Ice|
|Therapeutic Area||Atherosclerosis, Arthritis, Inflammation, Oncology/Cancer|
|Unit Size||1 Vial (10 doses)|
|Wave Length||680 nm|
Epifluorescence (2D) imaging of superficially,implanted mouse tumor xenograft models offers,a fast and simple method for assessing tumor,progression or response to therapy. This approach,for tumor assessment requires the use of near,infrared (NIR) imaging agents specific for different,aspects of tumor biology, and this Application,Note highlights the ease and utility of multiplex,NIR fluorescence imaging to characterize the,complex biology within tumors growing in a living,mouse. IntegriSense™ 750 detects avb3 integrin,expression, BombesinRSense™ 680 detects the upregulation of bombesin receptor,(associated with tumor proliferation), Transferrin-Vivo™ 750 detects increases in,transferrin receptor (due to increased iron metabolism), MMPSense® 680 is activated,by disease-related matrix-metalloproteases (secreted by tumor cells and tumor,associated macrophages), and ProSense® 750EX detects increases in cathepsin,activity (elevated in lysosomes of tumors and inflammatory cells). OsteoSense® 680,a bone turnover imaging agent, was used as a non-tumor imaging control. These,and multiple other PerkinElmer imaging agents, can be used to characterize tumor,biology, and in this set of studies the data shows that two different tumors, HeLa,(cervical cancer) and 4T1 (breast cancer), can differ in their pattern of labeling,intensities for six distinct biological imaging agents. Such an approach is likely to,prove valuable for the full biological characterization of tumors during progression,metastasis, or response to treatment.
We have demonstrated the ability of our Fluorescence Tomography (FMT 2500) in vivo imaging system and ProSense 680 to non-invasively visualize and quantify inflammation in the lung in a robust and validated manner. The consistency of the quantitative tomography, as well as its excellent correlation with BAL assessment of eosinophilia, provide a powerful toolkit for quantifying the therapeutic efficacy of dexamethasone treatment. Utilizing new and existing imaging agents, FMT imaging in asthma research provides useful, non-invasive tools for understanding pulmonary inflammation and for developing new therapeutics in vivo.